The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
* Greatly increase the company's current capacity to 90,000L and enable WuXi Biologics to initiate any project within four weeks * Offer flexible large-scale manufacturing services by implementing Scale-out strategy WUXI, China, Feb. 9, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.H...
WuXi Biologics Receives GMP Certification from Brazil's ANVISA
* First company in China to receive GMP certification for the production of biologics from the U.S. FDA, EMA and ANVISA WUXI, China, Dec. 28, 2020 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that ...
WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer
* The DS facility (MFG19) with 3x1000L perfusion and 6x2000L fed-batch capacity for vaccines and biologics is expected to be GMP ready in late 2021 * Complements WuXi Biologics' existing DP capacity in Germany * Capacity expansion allows WuXi Biologics to meet growing client demand worldwide...
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation
MUNICH and SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug conjugates (ADCs) towards IND-enabling studies. Tubulis has developed a dual platform approach to gene...
WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou
HANGZHOU, China, Nov. 20, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced its biologics integrated innovation center has been in operation inHangzhou, Zhejiang province, China. From process deve...
WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa
* Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) * WuXi Biologics to undertake commercial-scale manufacturing to support U.S. market launch SHANGHAI and LAUSANNE, Switzerland, Oct. 2...
Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines
SHANGHAI, Oct. 10, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, and WuXi Biologics ("WuXi Bio") (2269.HK) a...
WuXi Biologics Records Excellent Interim Results
Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to RMB736.1 Million Adjusted Net Profit Up 40.7% Y-o-Y to RMB734.0 Million Diluted EPS Up 55.9% Y-o-Y to RMB0.53 Adjusted Diluted EPS Up 38.5% Y-o-Y to RMB...
WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer
SHANGHAI and DUNDALK, Ireland, Aug. 6, 2020 /PRNewswire/ -- WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased to announce the appointment of Mr.Jian Dong as Chief Executive Officer (CEO). WuXi Vacci...
WuXi Biologics Awarded as "Most Honored Company" by Institutional Investor
SHANGHAI, Aug. 4, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it was awarded as "Most Honored Company" byInstitutional Investor , an international financial publication, based on the strength o...
Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day
SHANGHAI, June 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its 2nd Investor Day with the theme of "Embrace Change to Turn Challenges into Opportunities", was successfully held onJune 18. T...
WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing
* One of few third-party biosafety testing providers certified by EMA GMP standards inChina even Asia-Pacific region SUZHOU, China, June 16, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its f...
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
CRANBURY, NJ and SHANGHAI, June 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has signed a 10-year lease for a clinical manufacturing facility (MFG18) inCranbury, New Jersey. The new clin...
WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories
SHANGHAI and NEW YORK, May 28, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been recognized by Life Science Leader for the third year, achieving 2020 CMO Leadership Awards in six criter...
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States
SHANGHAI and WORCESTER, Mass., May 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and the Worcester Business Development Corporation (WBDC) announced today the successful signing of a land deal for WuXi Bio...
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
SHANGHAI and HOUSTON, April 30, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, today announced a strategic collaboration agreement...
WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility
* First GMP facility in WuXi Biologics to use robotic aseptic filling line for biologics * Demonstrated diverse and flexible aseptic filling capability while maintaining high-quality and controlled filling accuracy as well as aseptic assurance WUXI, China, April 28, 2020 /PRNewswire/ -- WuXi ...
WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany
SHANGHAI and LEVERKUSEN, Germany, April 22, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisition deal with Bayer for a drug product manufacturing plant in Leverkusen,Ge...
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection
SUZHOU, China, April 13, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency (EMA), wi...
WuXi Biologics Achieved Remarkable Results in 2019
57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted EPS of RMB0.76 and Adjusted Diluted EPS of RMB0.91, Increasing 58.3% and 59.6% Backlog Increased 40.2% to US$5.1 Billion Milestone Payments Surg...
